Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01964326 · ClinicalTrials.gov registry record · Phase 3
Actual Use Trial of Atorvastatin Calcium 10 mg
A Phase 3 study of Hypercholesterolemia, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,311
- Enrollment target
- 20
- Study locations
NCT01964326 is a Phase 3 study of Hypercholesterolemia that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 1,311 participants, above the 796-participant average among 62 other Hypercholesterolemia trials with a reported enrollment target (65% higher). The trial reports 20 study locations across 8 states.
The verdict
NCT01964326, a Phase 3 study of Hypercholesterolemia, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,311 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this actual use study is to simulate the over the counter use of atorvastatin calcium 10 mg.
Conditions Studied
Interventions
- DRUG Atorvastatin calcium 10 mg
Study Locations (20)
Minnesota
- Kemper Drug - Elk River
- Goodrich Pharmacy - Fridley
- Northfield Pharmacy - Northfield
- Cub Pharmacy - Rosemount
- Goodrich Pharmacy - Saint Francis
Alabama
- Robert's Discount Pharmacy - Hoover
- Pharmacy at the Pig - McCalla
- Pinson Discount Drugs - Pinson
Florida
- Garden Drug - Fort Lauderdale
- Pill Box Pharmacy and Medical Supply - Pembroke Pines
- Summerfield Pharmacy - Riverview
Arizona
- Community Clinical Pharmacy - Mesa
- Melrose Pharmacy - Phoenix
California
- Bi-Rite Quality Pharmacies - La Habra
- Parkview Compounding Pharmacy - Rancho Cucamonga
Georgia
- Sutton Family Pharmacy - Dalton
- Wynn's Pharmacy Inc. - Griffin
Missouri
- Albers' Medical Pharmacy - Kansas City
- Countryside Pharmacy - Savannah
Maryland
- Catonsville Pharmacy - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,311 participants |
| Start Date | 2013-10 |
| Est. Completion | 2014-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01964326
The ClinicalTrials.gov registry entry for NCT01964326 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,311 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 796-participant average among 62 other Hypercholesterolemia trials with a reported enrollment target (65% higher). The listed sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hypercholesterolemia appearing as the primary indexed condition, and to 1 intervention - of which Atorvastatin calcium 10 mg is the first listed.
NCT01964326 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Minnesota, Alabama, Florida.
Frequently Asked Questions
What is clinical trial NCT01964326 about?
NCT01964326 is a clinical study titled "Actual Use Trial of Atorvastatin Calcium 10 mg". The purpose of this actual use study is to simulate the over the counter use of atorvastatin calcium 10 mg.
What is the current status of trial NCT01964326?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,311 participants. The study started on 2013-10. Estimated completion is 2014-12.
What conditions does trial NCT01964326 study?
This clinical trial studies the following conditions: Hypercholesterolemia.
What interventions are being tested in trial NCT01964326?
The interventions under investigation include: Atorvastatin calcium 10 mg (DRUG).
Who is sponsoring clinical trial NCT01964326?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01964326 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypercholesterolemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension
ACTIVE NOT RECRUITING · Phase 3
-
Effect of a Decision Aid About Statin Use in Patients With Type 2 Diabetes Mellitus
COMPLETED · Phase 3
-
Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia
COMPLETED · Phase 3
-
Action to Control Cardiovascular Risk in Diabetes (ACCORD)
COMPLETED · Phase 3
-
A Study to Evaluate the Efficacy and Safety of Enlicitide Decanoate (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018) CORALreef AddOn
COMPLETED · Phase 3
-
GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.